Researchers develop new, highly-specific functional imaging probe to detect hypoxic tumors

Tumor detection using targeted fluorescent imaging probes is a promising technology that takes advantage of specific molecular events occurring in cancer tissues. However, currently available probes that use this technology fail to maximize their specificity for tumors because of strong off-target signals, and thus, have limited ability to detect small tumors in a short timespan after systemic injection.

In order to overcome these problems, Dr. Kizaka-Kondoh and his colleagues at Tokyo Institute of Technology developed a novel, highly-specific, functional imaging probe that can detect hypoxic tumors with HIF activity, which is a hallmark of malignancy and poor prognosis. In normoxic cells, the transcription factor HIF-1α is degraded by the action of E3 ubiquitin ligase on the oxygen-dependent degradation domain (ODD) of HIF-1α; however HIF-1α is stabilized and therefore, accumulates in hypoxic cancer cells. Therefore, a protein containing the ODD would be intact in hypoxic tumors, but destroyed in normoxic tissues. The scientists exploited this molecular mechanism to construct a tumor-specific probe called POL-N (Protein transduction domain [PTD]-ODD-Luciferase-Near-infrared [NIR] dye) which contained: 1) the ODD core, 2) a PTD for intracellular delivery, 3) red-shifted luciferase, and 4) a NIR fluorescent dye with peak emission around 700 nm. This design enabled intramolecular bioluminescence resonance energy transfer (BRET) between luciferase and the NIR dye leading to generation of NIR light only in HIF-active hypoxic cells (Figure a). The normoxic cells did not generate BRET signals because POL-N was recognized through the ODD and degraded by the E3 ubiquitin ligase. Consequently, POL-N minimized the off-target signals and maximized tumor-to-normal tissue (T/N) ratio, while generating long-wave (700 nm) signals critical for imaging of deep tissues in living animals.

The scientists confirmed that POL-N-generated BRET signals correlated with hypoxia and intratumoral HIF activity, and successfully detected tumors in live mice, which was almost impossible using conventional fluorescence imaging (Figure b). Although the fluorescent dye detached from the degraded POL-N probe stayed for some time in normoxic cells, the intact POL-N probe rapidly disappeared from the circulation and excretory organs, including the kidney and liver, dramatically reducing off-target BRET signals because they are generated from only intact POL-N, and thus increasing tumor/muscle and tumor/kidney signal ratios (Figure c). Importantly, the injection of the POL-N probe enabled tracking of metastases in the liver and gastrointestinal tract, which are otherwise extremely difficult to detect by conventional fluorescence imaging because of strong off-target signals.

This research demonstrates that the technology combining BRET and ubiquitin proteasome system (UPS)-recognizable motifs is a breakthrough approach for fast and highly sensitive detection of tumors. Because the function of many important biological factors is controlled by the UPS, this study also offers a general strategy in the design of highly-specific injectable imaging probes for monitoring aberrant activity of the UPS-regulated factors both in cultured cells and whole organisms, thus opening new avenues in molecular imaging.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
What is the difference in risk of early prostate cancer death between men at higher vs lower genetic risk?